Guardion Health Sciences Inc

Guardion Health Sciences, Inc.is a clinical nutrition and diagnostics company, which develops medical foods and medical devices in the ocular health space and develops nutraceutical products to provide supportive health benefits to consumers. The company was founded by Michael Favish in 2009 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardion Health Sciences, Inc. engages in the development and distribution of clinically supported dietary supplements and medical foods. The firm also offers science-based products and devices designed to support healthcare professionals, providers, patients, and consumers. The company was founded by Michael Favish in December 2009 and is headquartered in Houston, TX.

The stock price of Guardion Health Sciences Inc (NASDAQ: GHSI) increased by over 8% during intraday trading today. This is why it happened.

Guardion Health Sciences (GHSI) Stock: Over 8% Increase Explanation

Acquisition to Transform and Strengthen Guardion's  Clinical Nutrition Product Portfolio

Guardion Health Sciences to Acquire Activ Nutritional, LLC and Its Well-Known Viactiv® Brand of Products from Adare Pharmaceuticals, Inc.

Clinical Trial Intended to Demonstrate Improved Visual Function in Glaucoma Patients Taking GlaucoCetin® Clinical Trial Intended to Demonstrate Improved Visual Function in Glaucoma Patients Taking GlaucoCetin®

Guardion Health Sciences Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Company Provides Corporate Update and Overview of Growth Plans Company Provides Corporate Update and Overview of Growth Plans

Guardion Health Sciences Announces Financial Results for the Three Months and Year Ended December 31, 2020

Guardion Health Sciences is burning through its cash too fast. Be cautious with GHSI stock as the price won't rise without an acquisition.

Guardion Health Sciences Is Burning Through Its Cash Raise Too Fast

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutritional supplements, medical foods, and medical devices, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). On March 15, 2021, Guardion received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC (“Nasdaq”) stating that because Guardion's Company's common stock (the “Common Stock”) had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive trading days, its Common Stock had regained compliance with Nasdaq's Minimum Bid Price Rule.

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

The company maintains its Nasdaq listing, but at a price.

Why Guardion Health Sciences Stock Got Mashed on Monday

The stock price of Guardion Health Sciences (NASDAQ: GHSI) increased by 335.84% on Friday, February 26. This is why it happened.

GHSI Stock Price Increased 335.84%: Why It Happened

The stock price of Guardion Health Sciences, Inc. (NASDAQ: GHSI) fell over 27% during intraday trading. This is why it happened.

GHSI Stock Price Fell Over 27% Intraday: Why It Happened

Shares of Guardion Health Sciences Inc. tumbled 24.0% in premarket trading Friday, after the medical foods company focused on ocular health said it was implementing a 1-for-6 reverse stock split, to help maintain listing requirements. The reverse split will go into effect with the opening of trading on March 1, meaning stock price on Monday will start at six-times Friday's closing price.

Guardion Health stock tumbles after reverse stock split announcement

Recent at-the-market financings and warrant exercises have netted a combined $37.2 million in 2021, providing an effective cash runway for program execution and acquisition strategy implementation

Guardion Health Sciences Announces 1-for-6 Reverse Stock Split Effective Pre-Market Opening on Monday, March 1, 2021

Amedisys

Cardiff Oncology

Fulgent Genetics

Natera

Owens & Minor

Teladoc

Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlace.

7 Healthy Medical Stocks to Buy

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods, nutraceuticals and medical devices, with a focus in the ocular health marketplace, announced that its exclusive distributor in Malaysia, Ho Wah Genting Berhad (HWGB), has advised Guardion that Astramern Astra H (formerly Astramern Nutra H), an immune support dietary supplement designed and produced by the Company, has been granted product registration approval by the Malaysian National Pharmaceutical Regulatory Agency (“NPRA”).

Malaysia's Ho Wah Genting Berhad Advises Guardion Health Sciences That It Has received Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences

American Battery Technology Company

ObsEva

Safe Bulkers

IsoRay

Zomedica

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

7 Penny Stock Bubbles That Are About to Burst

SAN DIEGO, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods, nutraceuticals and medical devices, with a focus in the ocular health marketplace, announced that it has received a letter from Nasdaq granting it an exception until March 15, 2021 to evidence compliance with Nasdaq's $1.00 Minimum Bid Price Rule.

Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

Guardion Health Sciences (GHSI) is seeing a massive spike in its stock on Wednesday despite a lack of news concerning the company. The post GHSI Stock: 11 Things for Investors to Know About Guardion Health Sciences appeared first on InvestorPlace.

GHSI Stock: 11 Things for Investors to Know About Guardion Health Sciences

SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, today announces the appointment of Bret Scholtes, a veteran of the nutritional products industry for nearly a decade, as its President and Chief Executive Officer, and as a member of the Board of Directors, commencing January 6, 2021.

Guardion Health Sciences Appoints Seasoned Nutritional Products Industry Leader Bret Scholtes as President and Chief Executive Officer

SAN DIEGO, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, announced progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V

Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2020

New Study Published on October 26, 2020 in Peer-Reviewed Journal “Nutrients” New Study Published on October 26, 2020 in Peer-Reviewed Journal “Nutrients”

Guardion Health Sciences Announces Newly-Published Data Demonstrating Superior Visual Function and Macular Carotenoid Changes Using Guardion's Proprietary Lumega-Z® Formulation Compared to AREDS-2 Formulation

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing the following answers to frequently asked questions to its stockholders with regard to Proposal 4, which is being considered at the Company's Annual Stockholders' Meeting (the “Annual Meeting”) on October 29, 2020. Only stockholders of record on September 1, 2020, or the record date, are eligible to attend and vote on proposals presented at the Annual Meeting. The Board recommends a vote “FOR” Proposal 4.

Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders' Meeting

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, announced an investigator-initiated clinical trial of Lumega-Z, its flagship nutritional product which is now being marketed under the NutriGuard brand. This clinical trial, which is part of the Company's on-going investigator-driven studies program to support clinical claims for the Company's proprietary products, is designed to evaluate the impact of Lumega-Z on the restoration of the macular pigment and its relationship to the stabilization or recovery of vision. Depletion of the macular pigment at the back of the eye is a risk factor for vision loss related to age-related macular degeneration (“AMD”), glaucoma and other serious eye diseases.

Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing an update to shareholders with regard to its business plans. In conjunction with Guardion’s emphasis on differentiation of brands and the development and integration of an E-commerce platform, and the further development of clinically supported nutritional products and continued expansion into international markets, the Company has retained the investment banking firm of Corporate Finance Associates (“CFA”) to act as its exclusive financial advisor to assist management and the Board of Directors in the evaluation of strategic transactions and opportunities to enhance shareholder value.

Guardion Provides Update on Strategy, Business Plans and Initiatives

Annual stockholder meeting scheduled for Thursday, October 29, 2020

Guardion Announces Virtual Annual Meeting of Stockholders

Ho Wah Genting Berhad Receives Product Registration Approval For Astramern Nutra V Ho Wah Genting Berhad Receives Product Registration Approval For Astramern Nutra V

News for Guardion Health Sciences Inc Stock (GHSI)